Vizora日本語

Kyowa KirinKyowa Kirin Co.,Ltd.4151東証プライム医薬品FY ending Dec 2025, consolidated, IFRS

Kyowa Kirin FY ending Dec 2025 results

Kyowa Kirin brought in ¥496.8B in revenue.

Out of every ¥100 of sales, about ¥41 is left as operating profit.

Revenue changed +0.3% from the prior year.

What changed from last year

FY ending Dec 2024 → FY ending Dec 2025

Revenue
+0.3%¥495.6B → ¥496.8B
Gross profit
+1.6%¥362.9B → ¥368.9B
Net income attributable to owners
+12.0%¥59.9B → ¥67B
Operating cash flow
+42.3%¥67.9B → ¥96.6B
Free cash flow
Back to profit-¥37.4B → ¥13.1B

Results at a glance

  • Revenue for the FY ending Dec 2025 was ¥496.8B, almost unchanged from ¥495.6B (+0.3%).
  • Growth from newer drugs overseas and higher licensing income was offset by the restructuring of its Asia business and drug price cuts in Japan.
  • Net income rose +12.0% to ¥67B. Operating cash flow climbed to ¥96.6B (+42.3%), and free cash flow turned positive at ¥13.1B after a negative prior year.

What drove the change

  • Its own drugs such as Crysvita and Poteligeo grew in North America and Europe
  • Licensing income rose on higher royalties from AstraZeneca and an upfront payment from Boehringer Ingelheim
  • The Asia restructuring, Japanese price cuts and the end of the Dovobet sales partnership held revenue back
  • Lower SG&A and R&D spending lifted profit

Things to watch

  • Growing pressure on healthcare spending worldwide and harder drug development
  • Cyberattacks that could stop systems or leak data
  • Manufacturing or quality problems that could disrupt supply

Annual Securities Report (FY ending Dec 2025) / 経営者による財政状態、経営成績及びキャッシュ・フローの状況の分析 · Annual Securities Report (FY ending Dec 2025) / 事業等のリスク

Where the money goes

FY ending Dec 2024 → FY ending Dec 2025

※ Operating income is not disclosed; the chart goes straight to pretax income including investment gains

Where ¥100 of sales goes

For every ¥100 Kyowa Kirin sells, how much goes where, and how much is kept.

FY ending Dec 2025
Cost of sales
¥26
SG&A
¥33
Operating profit
¥41
Net profit kept
¥13

* This company does not report operating income, so it is calculated as gross profit minus SG&A. Equity-method income and dividends are not included, so net profit can be larger.

Annual margin trends

Gross margin74.2%
FY ending Dec 2020: 74.7%74.7%FY ending Dec 2021: 75.1%75.1%FY ending Dec 2022: 78.2%78.2%FY ending Dec 2023: 74.9%74.9%FY ending Dec 2024: 73.2%73.2%FY ending Dec 2025: 74.2%74.2%FY20FY21FY22FY23FY24FY25
Net margin13.5%
FY ending Dec 2020: 14.8%14.8%FY ending Dec 2021: 14.9%14.9%FY ending Dec 2022: 13.4%13.4%FY ending Dec 2023: 18.4%18.4%FY ending Dec 2024: 12.1%12.1%FY ending Dec 2025: 13.5%13.5%FY20FY21FY22FY23FY24FY25

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Sources

Show source documents (6)

  • EDINET (FSA Japan)

    有価証券報告書－第103期(2025/01/01－2025/12/31)

    ID S100XPTY2026-03-10Open

  • EDINET (FSA Japan)

    有価証券報告書－第102期(2024/01/01－2024/12/31)

    ID S100VDMK2025-03-11Open

  • EDINET (FSA Japan)

    有価証券報告書－第101期(2023/01/01－2023/12/31)

    ID S100T1DP2024-03-12Open

  • EDINET (FSA Japan)

    有価証券報告書－第100期(2022/01/01－2022/12/31)

    ID S100QCX22023-03-09Open

  • EDINET (FSA Japan)

    有価証券報告書－第99期(令和3年1月1日－令和3年12月31日)

    ID S100NMKA2022-03-08Open

  • EDINET (FSA Japan)

    有価証券報告書－第98期(令和2年1月1日－令和2年12月31日)

    ID S100KWXR2021-03-09Open

Extracted from XBRL: 42 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image